Global Infectious Disease Treatment Market Research Report: By Disease Type (Viral Diseases, Bacterial Diseases, Fungal Diseases, Parasitic Diseases and others), Treatment (Antibiotics, Antivirals, Antifungals, Anti-Parasitic and others), End User (Hospitals & Clinics, Ambulatory Care Centers and others) and Region (the Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2027

Market Scenario

Infectious diseases are the diseases caused by microorganisms such as viruses, bacteria, fungi or parasites. Infectious diseases are transmissible diseases which can be passed from person to person or some are transmitted by bites from insects or animals. There are many organisms living inside the human body which are normally harmless, but under certain conditions this microorganisms can cause various diseases. According to World Health Organization in 2015, there were 705,000 malaria cases reported in Western Pacific region.

Asia Pacific market is chiefly driven by increasing prevalence of different infectious diseases. Additionally, tropical climate, poor sanitation, humid weather has led to increase in incidence of infectious diseases in this region. Growing healthcare awareness and rising government funding’s in the developing countries further fuels the market growth in this region.

However, lack of availability of treatment for different infectious diseases restrain the market growth in this region.

Asia Pacific infectious disease diagnosis and treatment market is expected to grow at a CAGR of 7.8% during the forecast period.

Request Free Sample Copy at : https://www.marketresearchfuture.com/sample_request/7031

Asia Pacific Infectious Disease Diagnosis & Treatment Market –

Competitive Landscape

The infectious disease diagnosis and treatment market in Asia-Pacific region is growing owing to the increasing developments of key players like Lupin, Pfizer, Abbott, Cipla, and Johnson & Johnson in this region. The key players in this market have adopted strategies of maintaining their position in the market through mergers and acquisitions, strategic tie-ups and continuous new product launches.

In April 2018, Pfizer stated the approval of Breakthrough Therapy Designation for TRUMENBA (Meningococcal Group B Vaccine) from U.S. Food and Drug administration (FDA). TRUMENBA, first approved Breakthrough Therapy for MenB vaccine for active immunization in children aged one to nine years.

In November 2017, Cipla, an Indian pharmaceutical company stated the approval of Q-TIB drug from World Health Organization for prevention of tuberculosis infection in people infected with HIV. This approval allowed Cipla to market the TB prevention drug globally.

In October 2017, Lupin Limited, a multinational pharmaceutical company stated that LUPIN Inc., its US division acquired Symbiomix Therapeutics, LLC, a privately held company engaged in developing innovative therapies for gynecologic infections. Lupin expanded its branded women’s health specialty business with acquisition of Symbiomix and Solosec franchise.

In October 2017, Abbott, a global healthcare company announced acquisition of Alere Inc. With the acquisition, Abbott strengthened its position in in-vitro diagnostic market. This acquisition further increased the growth of infectious diseases diagnostic market in Asia Pacific region as both are key players for this market.

In May 2017, Alere Inc., a global manufacturer of point of care diagnostic test launched a rapid diagnostic test Alere Malaria Ag P.f, to detect malaria infections among asymptomatic patients. With this product launch, Alere expanded its product portfolio for malaria infection.

In February 2017, drug major Cipla stated the launch of adult Hepatitis B vaccine in Indian market. For this launch, Cipla entered into a co-exclusive agreement with Serum Institute of India Private Limited (SII) which allowed Cipla to market the vaccine for adult population and SII for children and adults.

In August 2016, Lupin announced acquisition of 21 branded drugs from Shionogi & Co., a Japanese pharmaceutical company for USD 150 million. The 21 branded drugs acquired covers therapeutic areas like central nervous system, oncology, cardiovascular and anti-infectives. With this acquisition, Lupin expanded in world’s second largest pharmaceutical market.

In September 2014, Cipla Limited declared a licensing agreement with Gilead Sciences, Inc., for developing, manufacturing and selling of hepatitis C treatment drugs Sofobuvir mono, Ledipasvir mono, combination of Ledipasvir and sofosbuvir with each other or with other active substances. With this agreement, Cipla manufactured and marketed Ledipasvir and Sofosbuvir in 91 countries including India.

Regional Analysis

Asia Pacific infectious disease diagnosis and treatment is divided into Japan, China, Australia, India, Republic of Korea and Rest of Asia Pacific. China dominates the infectious disease diagnosis and treatment market owing to growing prevalence of infectious diseases followed by India.

Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/infectious-disease-diagnosis-treatment-market-7031

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact:

Akash Anand

Market Research Future

+1 646 845 9312

Email: [email protected]